Organogenesis
NASDAQ: ORGOCanton, US · 1 known investors
Organogenesis develops and manufactures regenerative medicine products, including FDA-approved skin substitutes with living cells (such as Apligraf) used to treat diabetic foot ulcers and venous leg ulcers. Its portfolio spans advanced wound care, surgery, and sports medicine, serving clinicians and patients, with manufacturing and R&D facilities in Smithfield, Rhode Island.
BiotechHealthtechMedical Devices
Investors · 1
In the news
Organogenesis Q2 2026 earnings: Revenue falls 58% as losses widentradingkey.com · Aug 2026
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers - BioSpacebiospace.com · Jul 2026Frequently asked questions
- What does Organogenesis do?
- Organogenesis develops and manufactures regenerative medicine products, including FDA-approved skin substitutes with living cells (such as Apligraf) used to treat diabetic foot ulcers and venous leg ulcers. Its portfolio spans advanced wound care, surgery, and sports medicine, serving clinicians and patients, with manufacturing and R&D facilities in Smithfield, Rhode Island.
- Who are Organogenesis's investors?
- Organogenesis's investors include Khosla Ventures.
- Where is Organogenesis headquartered?
- Organogenesis is headquartered in Canton, US.